

Momentum Bioscience accelerates direct-from-blood sepsis diagnostic development with £2M grant from UKRI Horizon Europe Guarantee Extension

Oxfordshire, United Kingdom, Sept 26, 2023.

Momentum Bioscience Limited today announced that UK Research and Innovation (UKRI) has confirmed funding for the Company's successful application to the European Innovation Council's (EIC) Accelerator competition. The UKRI Horizon Europe Guarantee will contribute £2M towards developing Momentum's SepsiSTAT® product, a disruptive diagnostic test for microbial infection directly from whole blood in sepsis patients.

The EIC competition is a highly selective evaluation process, leading to Momentum winning the award as one of 32 out of 476 applicants. The process consists of multiple rounds assessed by industry experts and culminates in an expert panel interview.

SepsiSTAT is a direct-from-blood, automated sample preparation technique for sepsis patients where time to result is critical. The technology utilises proprietary methods to capture low levels of circulating organisms from whole blood and purify, concentrate and grow the organisms into a bespoke inoculum ready for identification, antimicrobial susceptibility, and next-generation sequencing.

Sumi Thaker, Chief Executive Officer of Momentum Bioscience, commented: "We are delighted to have won the EIC competition and receive grant funding support from UKRI. This validates the SepsiSTAT promise to radically accelerate identification and antibiotic susceptibility testing of sepsis-causing infections from 1-3 days using the current standard of care, down to 5-12hr. The Momentum team are determined to demonstrate a better way to support healthcare professionals managing this critical patient group, reduce antimicrobial resistance and lower healthcare costs."

About Momentum Bioscience:

Momentum Bioscience is developing tests for clinically-important infections where time to result matters. SepsiSTAT[®] is our direct-from-blood, rapid screening product, enabling existing products and workflows to yield results significantly faster than blood culture.

Momentum was founded in 2008. The Company is backed by its executive team, business angels and venture capital. It is headquartered near Cardiff and has an R&D facility near Oxford in the UK.

Contact Information:

Sumi Thaker Chief Executive Officer info@momentumbio.co.uk Tel: +44 (0)29 2167 7910 Web: <u>www.momentumbio.co.uk</u>

UK participants in Horizon Europe Project EIC Accelerator 2023 (HORIZON-EIC-2023-ACCELERATOR-01) are supported by UKRI grant number 10081004 (Momentum Bioscience Ltd.).